vs
Lantheus Holdings, Inc.（LNTH）与Alpha Teknova, Inc.（TKNO）财务数据对比。点击上方公司名可切换其他公司
Lantheus Holdings, Inc.的季度营收约是Alpha Teknova, Inc.的40.7倍（$406.8M vs $10.0M）。Lantheus Holdings, Inc.净利率更高（13.3% vs -47.7%，领先61.0%）。Alpha Teknova, Inc.同比增速更快（7.8% vs 4.0%）。Lantheus Holdings, Inc.自由现金流更多（$81.4M vs $-810.0K）。过去两年Lantheus Holdings, Inc.的营收复合增速更高（4.9% vs 3.7%）
Lantheus Holdings是一家全球性医疗保健企业，专注于研发、生产及商业化创新诊断显像剂与相关解决方案，产品覆盖肿瘤学、心脏病学、泌尿学等核心医疗领域，主要市场遍及北美及全球其他重点地区。
Alpha Teknova, Inc.是一家生命科学企业，研发并生产专用试剂、细胞培养基及定制实验室解决方案，服务生物制药、分子诊断及学术研究领域客户，主要面向北美市场，为药物研发、诊断测试及生命科学研究流程提供支持。
LNTH vs TKNO — 直观对比
营收规模更大
LNTH
是对方的40.7倍
$10.0M
营收增速更快
TKNO
高出3.8%
4.0%
净利率更高
LNTH
高出61.0%
-47.7%
自由现金流更多
LNTH
多$82.2M
$-810.0K
两年增速更快
LNTH
近两年复合增速
3.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $406.8M | $10.0M |
| 净利润 | $54.1M | $-4.8M |
| 毛利率 | 59.2% | 32.5% |
| 营业利润率 | 19.0% | -46.2% |
| 净利率 | 13.3% | -47.7% |
| 营收同比 | 4.0% | 7.8% |
| 净利润同比 | 558.8% | 16.8% |
| 每股收益（稀释后） | $0.86 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LNTHTKNO
| Q4 25 | $406.8M | $10.0M | ||
| Q3 25 | $384.0M | $10.5M | ||
| Q2 25 | $378.0M | $10.3M | ||
| Q1 25 | $372.8M | $9.8M | ||
| Q4 24 | $391.1M | $9.3M | ||
| Q3 24 | $378.7M | $9.6M | ||
| Q2 24 | $394.1M | $9.6M | ||
| Q1 24 | $370.0M | $9.3M |
净利润LNTHTKNO
| Q4 25 | $54.1M | $-4.8M | ||
| Q3 25 | $27.8M | $-4.3M | ||
| Q2 25 | $78.8M | $-3.6M | ||
| Q1 25 | $72.9M | $-4.6M | ||
| Q4 24 | $-11.8M | $-5.7M | ||
| Q3 24 | $131.1M | $-7.6M | ||
| Q2 24 | $62.1M | $-5.4M | ||
| Q1 24 | $131.1M | $-8.1M |
毛利率LNTHTKNO
| Q4 25 | 59.2% | 32.5% | ||
| Q3 25 | 57.9% | 30.7% | ||
| Q2 25 | 63.8% | 38.7% | ||
| Q1 25 | 63.8% | 30.7% | ||
| Q4 24 | 63.5% | 23.0% | ||
| Q3 24 | 63.9% | 0.9% | ||
| Q2 24 | 64.9% | 29.2% | ||
| Q1 24 | 65.4% | 23.8% |
营业利润率LNTHTKNO
| Q4 25 | 19.0% | -46.2% | ||
| Q3 25 | 11.4% | -38.4% | ||
| Q2 25 | 23.3% | -32.9% | ||
| Q1 25 | 27.4% | -50.7% | ||
| Q4 24 | 29.1% | -60.7% | ||
| Q3 24 | 35.3% | -77.6% | ||
| Q2 24 | 26.1% | -53.0% | ||
| Q1 24 | 28.8% | -86.0% |
净利率LNTHTKNO
| Q4 25 | 13.3% | -47.7% | ||
| Q3 25 | 7.2% | -41.0% | ||
| Q2 25 | 20.8% | -34.7% | ||
| Q1 25 | 19.6% | -47.4% | ||
| Q4 24 | -3.0% | -61.7% | ||
| Q3 24 | 34.6% | -79.0% | ||
| Q2 24 | 15.8% | -55.8% | ||
| Q1 24 | 35.4% | -87.2% |
每股收益（稀释后）LNTHTKNO
| Q4 25 | $0.86 | $-0.08 | ||
| Q3 25 | $0.41 | $-0.08 | ||
| Q2 25 | $1.12 | $-0.07 | ||
| Q1 25 | $1.02 | $-0.09 | ||
| Q4 24 | $-0.18 | $-0.09 | ||
| Q3 24 | $1.79 | $-0.15 | ||
| Q2 24 | $0.88 | $-0.13 | ||
| Q1 24 | $1.87 | $-0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $359.1M | $21.3M |
| 总债务越低越好 | $568.7M | $13.1M |
| 股东权益账面价值 | $1.1B | $68.8M |
| 总资产 | $2.2B | $103.6M |
| 负债/权益比越低杠杆越低 | 0.52× | 0.19× |
8季度趋势，按日历期对齐
现金及短期投资LNTHTKNO
| Q4 25 | $359.1M | $21.3M | ||
| Q3 25 | $382.0M | $22.1M | ||
| Q2 25 | $695.6M | $24.0M | ||
| Q1 25 | $938.5M | $26.3M | ||
| Q4 24 | $912.8M | $30.4M | ||
| Q3 24 | $866.4M | $31.7M | ||
| Q2 24 | $757.0M | $18.6M | ||
| Q1 24 | $718.3M | $21.6M |
总债务LNTHTKNO
| Q4 25 | $568.7M | $13.1M | ||
| Q3 25 | $567.9M | $13.1M | ||
| Q2 25 | $566.8M | $13.0M | ||
| Q1 25 | $566.1M | $13.0M | ||
| Q4 24 | $565.3M | $9.4M | ||
| Q3 24 | $613.0K | $10.9M | ||
| Q2 24 | $563.2M | $12.3M | ||
| Q1 24 | $562.5M | $13.2M |
股东权益LNTHTKNO
| Q4 25 | $1.1B | $68.8M | ||
| Q3 25 | $1.1B | $72.7M | ||
| Q2 25 | $1.2B | $76.1M | ||
| Q1 25 | $1.2B | $78.6M | ||
| Q4 24 | $1.1B | $82.4M | ||
| Q3 24 | $1.2B | $87.3M | ||
| Q2 24 | $1.0B | $78.9M | ||
| Q1 24 | $945.5M | $83.4M |
总资产LNTHTKNO
| Q4 25 | $2.2B | $103.6M | ||
| Q3 25 | $2.3B | $107.6M | ||
| Q2 25 | $2.1B | $110.5M | ||
| Q1 25 | $2.1B | $114.0M | ||
| Q4 24 | $2.0B | $118.8M | ||
| Q3 24 | $2.0B | $124.1M | ||
| Q2 24 | $1.9B | $115.4M | ||
| Q1 24 | $1.8B | $120.8M |
负债/权益比LNTHTKNO
| Q4 25 | 0.52× | 0.19× | ||
| Q3 25 | 0.51× | 0.18× | ||
| Q2 25 | 0.49× | 0.17× | ||
| Q1 25 | 0.49× | 0.17× | ||
| Q4 24 | 0.52× | 0.11× | ||
| Q3 24 | 0.00× | 0.12× | ||
| Q2 24 | 0.55× | 0.16× | ||
| Q1 24 | 0.59× | 0.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $90.2M | $-462.0K |
| 自由现金流经营现金流 - 资本支出 | $81.4M | $-810.0K |
| 自由现金流率自由现金流/营收 | 20.0% | -8.1% |
| 资本支出强度资本支出/营收 | 2.2% | 3.5% |
| 现金转化率经营现金流/净利润 | 1.67× | — |
| 过去12个月自由现金流最近4个季度 | $354.1M | $-9.8M |
8季度趋势，按日历期对齐
经营现金流LNTHTKNO
| Q4 25 | $90.2M | $-462.0K | ||
| Q3 25 | $105.3M | $-2.0M | ||
| Q2 25 | $87.1M | $-2.1M | ||
| Q1 25 | $107.6M | $-4.1M | ||
| Q4 24 | $157.7M | $-936.0K | ||
| Q3 24 | $175.1M | $-2.1M | ||
| Q2 24 | $84.7M | $-2.8M | ||
| Q1 24 | $127.2M | $-6.6M |
自由现金流LNTHTKNO
| Q4 25 | $81.4M | $-810.0K | ||
| Q3 25 | $94.7M | $-2.4M | ||
| Q2 25 | $79.1M | $-2.3M | ||
| Q1 25 | $98.8M | $-4.3M | ||
| Q4 24 | $141.4M | $-1.5M | ||
| Q3 24 | $159.3M | $-2.4M | ||
| Q2 24 | $73.5M | $-3.0M | ||
| Q1 24 | $119.0M | $-6.7M |
自由现金流率LNTHTKNO
| Q4 25 | 20.0% | -8.1% | ||
| Q3 25 | 24.7% | -22.6% | ||
| Q2 25 | 20.9% | -22.4% | ||
| Q1 25 | 26.5% | -44.0% | ||
| Q4 24 | 36.1% | -16.2% | ||
| Q3 24 | 42.0% | -25.0% | ||
| Q2 24 | 18.7% | -30.7% | ||
| Q1 24 | 32.2% | -71.8% |
资本支出强度LNTHTKNO
| Q4 25 | 2.2% | 3.5% | ||
| Q3 25 | 2.8% | 3.7% | ||
| Q2 25 | 2.1% | 2.0% | ||
| Q1 25 | 2.3% | 2.1% | ||
| Q4 24 | 4.2% | 6.1% | ||
| Q3 24 | 4.2% | 3.5% | ||
| Q2 24 | 2.8% | 1.2% | ||
| Q1 24 | 2.2% | 1.2% |
现金转化率LNTHTKNO
| Q4 25 | 1.67× | — | ||
| Q3 25 | 3.79× | — | ||
| Q2 25 | 1.11× | — | ||
| Q1 25 | 1.47× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.34× | — | ||
| Q2 24 | 1.36× | — | ||
| Q1 24 | 0.97× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LNTH
| Radiopharmaceutical Oncology | $240.2M | 59% |
| Definity | $85.3M | 21% |
| Strategic Partnerships And Other | $23.3M | 6% |
| Techne Lite | $21.0M | 5% |
| Licenseand Royalty Revenues | $17.4M | 4% |
| Other | $13.6M | 3% |
| Other Precision Diagnostics | $5.9M | 1% |
TKNO
| Lab Essentials | $6.8M | 68% |
| Clinical Solutions | $2.7M | 27% |
| Other | $435.0K | 4% |
